| Cancer specific survival | Progression free survival | ||||||
---|---|---|---|---|---|---|---|---|
 | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||
 | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P |
MCM4 | ||||||||
 Negative | 1 (Reference) | 0.0366 | 1 (Reference) | 0.3838 | 1 (Reference) | 0.0022 | 1 (Reference) | 0.0090 |
 Positive | 3.76 (1.24–16.22) |  | 1.80 (0.48–6.74) |  | 5.19 (2.01–17.60) |  | 5.07 (1.73–21.62) |  |
Ki-67 | ||||||||
 Negative | 1 (Reference) | 0.0841 |  |  | 1 (Reference) | 0.1166 |  |  |
 Positive | 2.27 (0.87–5.76) |  |  |  | 1.82 (0.83–3.78) |  |  |  |
PD-L1 in TCs | ||||||||
 Negative | 1 (Reference) | 0.0012 | 1 (Reference) | 0.2213 | 1 (Reference) | 0.0093 | 1 (Reference) | 0.2009 |
 Positive | 4.82 (1.86–12.49) |  | 2.10 (0.64–6.94) |  | 2.97 (1.31–6.76) |  | 1.85 (0.72–4.77) |  |
PD-L1 in TILs | ||||||||
 Negative | 1 (Reference) | 0.0073 | 1 (Reference) | 0.1003 | 1 (Reference) | 0.3858 |  |  |
 Positive | 3.58 (1.41–9.10) |  | 2.62 (0.83–8.26) |  | 1.40 (0.65-3.00) |  |  |  |
CD44v9 | ||||||||
 Negative | 1 (Reference) | 0.0400 | 1 (Reference) | 0.1258 | 1 (Reference) | 0.0155 | 1 (Reference) | 0.0132 |
 Positive | 3.03 (1.00-8.73) |  | 2.33 (0.79–6.86) |  | 2.78 (1.17–6.27) |  | 2.87 (1.20–6.51) |  |
HER2 | ||||||||
 Negative | 1(Reference) | 0.8354 |  |  | 1(Reference) | 0.6696 |  |  |
 Positive | 1.14 (0.33–3.94) |  |  |  | 1.25 (0.44–3.61) |  |  |  |
EGFR | ||||||||
 Negative | 1(Reference) | 0.3310 |  |  | 1(Reference) | 0.1024 |  |  |
 Positive | 1.63 (0.61–4.34) |  |  |  | 1.89 (0.88–4.03) |  |  |  |
FGFR3 | ||||||||
 Negative | 1(Reference) | 0.1954 |  |  | 1(Reference) | 0.3400 |  |  |
 Positive | 0.44 (0.13–1.52) |  |  |  | 0.66 (0.28–1.54) |  |  |  |
p53 | ||||||||
 Negative | 1 (Reference) | 0.3782 |  |  | 1 (Reference) | 0.2433 |  |  |
 Positive | 1.55 (0.54–4.01) |  |  |  | 1.57 (0.70–3.29) |  |  |  |